Clinical Trial Update: Safety and Efficacy Evaluation of AIV001 in Nonmelanoma Skin Cancer of the Low Risk Basal Cell Carcinoma Subtype [Phase 1, Phase 2]

View source ↗

Summary

AiViva BioPharma reports completion of Phase 1/2 trials evaluating AIV001 for safety and efficacy in nonmelanoma skin cancer, focusing on superficial and nodula…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Basal Cell Carcinoma
• Nonmelanoma Skin Cancer

Drugs mentioned

• AIV001

Snippet

Sponsor: AiViva BioPharma, Inc. | Conditions: Superficial Basal Cell Carcinoma, Nodular Basal Cell Carcinoma | Phase 1, Phase 2 | Status: COMPLETED